T. Rowe Price Associates
DNTH icon

T. Rowe Price Associates’s Dianthus Therapeutics DNTH Stock Holding History

T. Rowe Price Associates’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$96.3M Buy
1,146,948
+530,915
+86% +$30.7M 0.01% 622
2025
Q4 		$25.4M Buy
616,033
+399,898
+185% +$15.5M ﹤0.01% 1007
2025
Q3 		$8.51M Buy
216,135
+205,443
+1,921% +$5.25M ﹤0.01% 1267
2025
Q2 		$200K Buy
10,692
+201
+2% +$3.77K ﹤0.01% 2714
2025
Q1 		$191K Buy
10,491
+1,023
+11% +$22.5K ﹤0.01% 2662
2024
Q4 		$207K Buy
9,468
+1,647
+21% +$42.4K ﹤0.01% 2668
2024
Q3 		$215K Buy
+7,821
New +$218K ﹤0.01% 2630
2021
Q3 		– Sell
-1,410
Closed -$221K – 2950
2021
Q2 		$221K Buy
+1,410
New +$259K ﹤0.01% 2693

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates's DNTH Position: Q1 2026 in Review

T. Rowe Price Associates increased its Dianthus Therapeutics (DNTH) stake by 86% in Q1 2026, buying an estimated $30.7M and bringing the position to 1,146,948 shares worth $96.3M. The position accounts for 0.01% of the portfolio, ranked #622.

T. Rowe Price Associates first reported a position in DNTH in Q2 2021 and has held it in 8 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • T. Rowe Price Associates held 1,146,948 shares of Dianthus Therapeutics worth $96.3M as of Q1 2026.
  • T. Rowe Price Associates bought 530,915 Dianthus Therapeutics shares in Q1 2026, an estimated $30.7M.
  • Dianthus Therapeutics made up 0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #622 holding.
  • T. Rowe Price Associates first reported a position in Dianthus Therapeutics in Q2 2021 and has held it in 8 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.